Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple score cut down on unnecessary lung scans?

NCT ID NCT06015529

Diagnosis Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tested a new way to decide if someone with a suspected blood clot in the lung needs a scan. The 4PEPS score uses 12 simple factors and a blood test to classify risk into four levels. Over 3,000 patients in 20 emergency departments took part. The goal was to see if using this score could safely reduce the number of CT scans and other imaging tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
4PEPS diagnostic strategy (a clinical scoring system using 12 variables and D-dimer levels)
What this could lead to
If successful, this strategy could reduce unnecessary chest scans and radiation exposure for patients with suspected pulmonary embolism, while maintaining safety.
What could go wrong
The trial is completed but results are not yet published. The strategy may not reduce imaging as hoped, or could miss some cases of pulmonary embolism.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

3,084 people

The number who actually took part.

Started

Nov 2023

Finished

Nov 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Admission to an emergency department participating in the study. * Suspected PE due to thoracic symptoms (dyspnea, chest pain, or hemoptysis) and/or syncope without any other obvious explanation after clinical examination and possible additional first-line tests (ECG, chest X-ray, or routine lab work-up). Exclusion Criteria: * Age \< 18 years. * Known result of a specific diagnostic imaging examination for PE (thoracic CT angiography, pulmonary scintigraphy, or venous ultrasound of the lower limbs). * Hemodynamic instability (systolic blood pressure \< 90 mmHg or more than 40 mmHg lower than usual for more than 15 min). * Curative dose of anticoagulant in place for more than two days prior to inclusion. * Pregnant or parturient patient. * Patient in detention by judicial or administrative decision. * Patient undergoing compulsory psychiatric treatment. * Patient placed under a legal protection measure. * Patient who objects to participating in the research (preliminary phase) or is unable to give free and informed consent (active phase).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary embolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary embolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary embolism

Contacts and locations

Locations

  • AP HP Clamart

    Clamart, France

  • CH Agen

    Agen, France

  • CH Argenteuil

    Argenteuil, France

  • CH Arpajon

    Arpajon, France

  • CH La Rochelle

    La Rochelle, France

  • CH Rochefort

    Rochefort, France

  • CH Troyes

    Troyes, France

  • CH Versailles

    Le Chesnay, France

  • CHR Metz Thionville

    Metz, France

  • CHU Angers

    Angers, 49000, France

  • CHU Clermont Ferrand

    Clermont-Ferrand, France

  • CHU Grenoble

    Grenoble, France

  • CHU Limoges

    Limoges, France

  • CHU Liège

    Liège, Belgium

  • CHU Lyon

    Lyon, France

  • CHU Nantes

    Nantes, France

  • CHU Nice

    Nice, France

  • CHU Poitiers

    Poitiers, France

  • CHU Rouen

    Rouen, France

  • CHU Toulouse

    Toulouse, France

  • CHU Tours

    Tours, France

  • Cliniques Bruxelles

    Brussels, Belgium

  • GH Paris

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.